NCT00975767终止1 期
A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 126
- 试验地点
- 5
- 主要终点
- Phase I: Safety profile (including maximum tolerated dose and dose limiting toxicities)
研究概览
简要总结
The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with advanced metastatic or unresectable solid malignancy that is refractory to standard therapy and/or existing therapies.
- •Evaluable disease.
- •Documented progressive disease during or following most recent treatment regimen.
- •Adequate hepatic parameters.
- •Age ≥18 years.
- •Life expectancy greater than 3 months.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate renal function.
- •Adequate bone marrow function.
- •Capable of understanding and complying with the protocol and written informed consent.
- •Negative pregnancy test for women of childbearing potential.
- •Use of adequate contraception as needed.
- •Subjects consenting to optional fresh biopsies, must not require concurrent anticoagulation medication.
- •Histologically or cytologically confirmed advanced Stage 3b or 4 NSCLC.
- •Measurable disease per RECIST.
- •At least one prior chemotherapy regimen for advanced disease.
- •No prior erlotinib or docetaxel therapy.
- •Documented progressive disease during or following most recent treatment regimen.
- •Adequate hepatic parameters.
- •Age ≥18 years.
- •Life expectancy greater than 3 months.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate renal function.
- •Adequate bone marrow function.
- •Capable of understanding and complying with the protocol and written informed consent.
- •Negative pregnancy test for women of childbearing potential.
- •Use of adequate contraception as needed.
排除标准
- •Recent anticancer treatment.
- •Prior treatment with an investigational cmet inhibitor or HCF inhibitor or antibody.
- •Uncontrolled concurrent illness.
- •History of bleeding diathesis or coagulopathy.
- •History of stroke or transient ischemic attack.
- •History of a cardiovascular illness.
- •QT interval corrected for heart rate (QTc) >470 msec.
- •Left ventricular ejection fraction (LVEF) <50%.
- •Immunocompromised subjects.
- •Lack of recovery to grade ≤1 from significant adverse events due to antineoplastic agents, investigational drugs, or other medications administered prior to study enrollment.
- •Symptomatic or uncontrolled brain metastases requiring current treatment.
- •Active gastrointestinal conditions or a history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess.
- •History of other malignancy treated with curative intent within the 5 previous years.
- •Lung tumor lesions with increased likelihood of bleeding.
- •History of major surgery within 28 days of first receipt of study drug.
- •History of autologous bone marrow transplant (BMT) within the previous five years, or subjects with organ transplants or allogeneic BMT.
- •Nursing or pregnant women; female subjects of childbearing potential must have a negative pregnancy test at screening.
- •Unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of oral drugs.
- •Any other condition or finding that in the opinion of the Investigator or Medical Monitor may render the subject at excessive risk for treatment complications or may render difficult the evaluation of treatment response.
- •Allergy or hypersensitivity to components of either the MGCD265, erlotinib or docetaxel formulations (depending on the group that the subject is assigned to).
研究组 & 干预措施
MGCD265+erlotinib
Experimental
干预措施: MGCD265+erlotinib (Drug)
MGCD265+docetaxel
Experimental
干预措施: MGCD265+docetaxel (Drug)
结局指标
主要结局
Phase I: Safety profile (including maximum tolerated dose and dose limiting toxicities)
时间窗: 1 year
Phase II: Antitumor activity of MGCD265+erlotinib and MGCD265+docetaxel
时间窗: 1 year
次要结局
- Phase I: Pharmacokinetic profiles of MGCD265+erlotinib and MGCD265+docetaxel(2 months)
- Phase I and Phase II: Pharmacodynamic profiles of MGCD265+erlotinib and MGCD265+docetaxel(1 year)
- Phase I: Antitumor activity of MGCD265+erlotinib and MGCD265+docetaxel.(1 year)
- Phase II: Safety profile of MGCD265+erlotinib and MGCD265+docetaxel;(1 year)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
This is a study to assess tumour response to MGCD265 in Patients with Locally Advanced or Metastatic non-small cell lung cancer with genetic alternation of MET.EUCTR2015-002070-21-GBMirati Therapeutics, Inc.290
进行中（未招募）
1 期
This is a study to assess tumor response to MGCD265 in Patients with Locally Advanced or Metastatic non-small cell lung cancer with genetic alternation of MET.EUCTR2015-002070-21-HUMirati Therapeutics, Inc.290
进行中（未招募）
1 期
This is a study to assess tumor reponse to MGCD265 in Patients with Locally Advanced or Metastatic non-small cell lung cancer with genetic alternation of MET.ocally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002070-21-ESMirati Therapeutics, Inc.290
进行中（未招募）
1 期
This is a study to assess tumor response to MGCD265 in Patients with Locally Advanced or Metastatic non-small cell lung cancer with genetic alternation of MET.EUCTR2015-002070-21-PLMirati Therapeutics, Inc.290
进行中（未招募）
1 期
This is a study to assess tumor response to MGCD265 in Patients with Locally Advanced or Metastatic non-small cell lung cancer with genetic alternation of MET.ocally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002070-21-ITMIRATI THERAPEUTICS INCORPORATED68